Patent: 10,583,190
✉ Email this page to a colleague
Summary for Patent: 10,583,190
Title: | Methods of treating psoriasis using IL-17 antibodies |
Abstract: | The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody. |
Inventor(s): | Guettner; Achim (Binzen, DE), Machacek; Matthias (Allschwil, CH), Papavassilis; Charis (Loerrach, DE), Sander; Oliver (Basel, CH) |
Assignee: | NOVARTIS AG (Basel, CH) |
Application Number: | 15/630,577 |
Patent Claims: | see list of patent claims |
Details for Patent 10,583,190
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2030-10-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2030-10-08 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2030-10-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |